Instead of a complete block in B-cell maturation, we observed a lower frequency of the CD19+/CD34− B-cell population in the bone marrow of mice transplanted with HSPCs from patients with XLA if compared with WT HSPCs transplanted mice with gene editing reverting this phenotype. The gene discussed is CD34; the disease is Bruton-type agammaglobulinemia.